CLINICAL RESEARCH PROTOCOL
INITIAL REVIEW APPLICATION

PRINCIPAL INVESTIGATOR (Name of NIH Employee, Institute/Branch, Address, Telephone and email):

PROTOCOL TITLE:

ABBREVIATED TITLE (30 characters or less):

PROPOSED START DATE: _____ END DATE: _____ TOTAL SUBJECTS TO BE ACCRUED (Attach target table for Phase 3-4): _____

MULTI-SITE COLLABORATION:
Is this a multi-site collaboration? ☐ Yes (complete this section) ☐ No
Will subjects participate on the protocol at the NIH CC? ☐ Yes ☐ No
Will subjects participate on the protocol at other sites? ☐ Yes ☐ No
If yes, are the sites ☐ Domestic ☐ Foreign ☐ Both
Is NIH the coordinating site?
☐ Yes. For each participating site, provide: Institution name, address, investigator(s), indicate if subjects will be recruited and if they are, include a contact name on attached sheet/protocol face sheet.
☐ No. Coordinating Site is_____

REQUESTED ACCRUAL EXCLUSION (Check all that apply):
☐ None ☐ Asian
☐ Male ☐ Black or African American
☐ Female ☐ White
☐ Children <18 ☐ Hispanic or Latino
☐ American Indian/ Alaskan Native ☐ Native Hawaiian or Pacific Islander

SUBJECT ACCRUAL CHARACTERISTICS:
Minimum Age Permitted _____
Maximum Age Permitted_____
Pediatric ☐ None ☐ <2 Yr. ☐ 2-6 Yrs. ☐ 7-17 Yrs.
Protocol involves healthy volunteers? ☐ Yes ☐ No
Are Healthy Volunteers NIH Employees? ☐ Yes ☐ No
Does the protocol permit self referral? ☐ Yes ☐ No
Will the protocol involve adults unable to give informed consent? ☐ Yes ☐ No

PROTOCOL TYPE: (Check one):
☐ Screening
☐ Training
☐ Natural History – Disease Progression/ Physiology
☐ Natural History – Sample/Data Collection or Analysis (Recruiting Patients)
☐ Natural History – Sample/Data Collection or Analysis (Not Recruiting Patients)
☐ Pharmacokinetics/Dynamics
☐ Clinical Trial: Identify Phase (Check one)
☐ Phase 0 ☐ Phase 1 ☐ Phase 1-2
☐ Phase 2 ☐ Phase 3 ☐ Phase 4

If a Phase 3 Clinical Trial, is analysis for sex, racial/ethnic subgroups required according to the NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research? ☐ Yes ☐ No ☐ N/A

KEY WORDS (Words or phrase that describe the protocol.)
1. _____
2. _____
3. _____
4. _____
5. _____

IONIZING RADIATION USE (X-rays, e.g., CT; radioisotopes, e.g. PET; etc.): check all that apply
☐ None ☐ Medically indicated ☐ Research indicated*
*Complete NIH-88-23a, and attach to this application. Send a copy of entire protocol and NIH-88-23a to Chair, Radiation Safety for concurrent review).

INVESTIGATIONAL NEW DRUG/DEVICE: ☐ None ☐ IND ☐ IDE
*If reporting more than one IND/IDE, list on attached sheet.
FDA No. _____.
IND/IDE Name: _____.
Sponsor: _____.
Who is the manufacturer of the above entity: _____

Does the protocol involve a Tech Transfer Agreement? ☐ Yes ☐ No

Does the protocol involve a drug/device/product that may lead to you or the NIH receiving payment and/or royalties?
☐ Yes (Append a statement of disclosure)
☐ No

Has the NIH IRP COI Guide been distributed to NIH Investigators?
☐ Yes ☐ No

Has the NIH IRP COI Guide been distributed to Non-NIH Investigators?
☐ Yes ☐ No ☐ N/A

CONFLICTS OF INTEREST REVIEW:
Date submitted to IC DEC:_____ Date cleared by IC DEC:_____

Is an Extramural Investigator an ADJUNCT PRINCIPAL INVESTIGATOR? ☐Yes ☐No
Name of Adjunct PI: _____

MEDICAL ADVISORY INVESTIGATOR (if necessary) Name, Inst/Branch, Telephone, Address, Email and initial line:
_____

LEAD ASSOCIATE INVESTIGATOR – Name, Inst/Branch, Telephone, Address, Email. Check box if an NIH employee and initial line:
☐_____

RESEARCH CONTACT: Name, Inst/Branch, Telephone, Address, Email. Check box if an NIH employee and initial line:
☐_____

ASSOCIATE INVESTIGATOR(S): Name, Institute/Branch, Telephone, Address, Email. Check box if an NIH employee and initial line. Attach list if necessary.
1. ☐ _____
2. ☐ _____
3. ☐ _____
4. ☐ _____
5. ☐ _____

(Principal Investigator: Be sure to include PRECIS <=400 words as first section of protocol)

SIGNATURE	_____ Principal Investigator	_____ Print/Type Name	Date _____		Send to Accountable Investigator
RECOMMENDATION	_____ Accountable Investigator	_____ Print/Type Name	Date _____		Send to Branch Chief, or CC Dept. Head of Accountable Investigator
	_____ Br. Chief/CC Dept. Head of Acct. Invest.	_____ Print/Type Name	Date _____		Send to Institute/Center Scientific Review Committee
APPROVALS	_____ For Institute/Center Scientific Review Comm.	_____ Print/Type Name	Date _____		Send to Clinical Director
	_____ Clinical Director	_____ Print/Type Name	Date _____		Send to Chair, Institutional Review Board
	_____ Chair, For Institutional Review Board	_____ Print/Type Name	Date _____ Protocol & Consent Approval Completed		Send to Office of Protocol Services, through IRB Protocol Coordinator
PATIENT SAFETY/ RESOURCE REVIEW	_____ Director, Clinical Center	_____ Print/Type Name	Date _____		Return to Office of Protocol Services, (10/1S231B)
COMPLETION	_____ Protocol Specialist	Date _____	**PROTOCOL NO.**		

The following data elements are required by the National Library of Medicine for posting on clintrials.gov and meets the registration requirements set forth by the International Committee of Medical Journal Editors (ICMJE) for publishing. http://www.clinicaltrials.gov/

CONDITIONS: Select up to 5 primary diseases or conditions being studied, using NLM Medical Subject Heading (MeSH) controlled vocabulary. The conditions are used to index studies. http://www.nlm.nih.gov/mesh/MBrowser.html

1. _____ 4. _____

2. _____ 5. _____

3. _____

STUDY TYPE: Nature of the investigation. Select Interventional or Observational, in addition to the most appropriate term describing the protocol for each of the corresponding categories.

☐ **Interventional Studies**	☐ **Observational Studies**
Purpose: Reason for the protocol ☐ Treatment ☐ Prevention ☐ Diagnosis ☐ Educate/Train Study Design: participant selection ☐ Randomized Trial ☐ Non-randomized Trial Masking: knowledge of intervention ☐ Open ☐ Single Blind ☐ Double Blind Control: nature of the interventional control ☐ Placebo ☐ Active ☐ Uncontrolled ☐ Historical ☐ Dose Comparison Assignment: intervention groups ☐ Single Group ☐ Parallel ☐ Cross-over ☐ Factorial ☐ Expanded Access Endpoint: primary outcome that the protocol is designed to evaluate ☐ Safety ☐ Efficacy ☐ Safety/Efficacy ☐ Bio-equivalence ☐ Bio-availability ☐ Pharmacokinetics ☐ Pharmacodynamics ☐ Pharmacokinetics/pharmacodynamics	Purpose: reason for the protocol ☐ Natural History ☐ Screening ☐ Psychosocial Duration of Sampling: protocol sample in ☐ Longitudinal ☐ Cross-sectional Selection Method: sample selection ☐ Targeted Population ☐ Random Sample ☐ Case Control Timing: data collection period ☐ Retrospective ☐ Prospective ☐ Both

COMPLETE FOR INTERVENTIONAL STUDIES ONLY

INTERVENTIONS: Provide up to 10 primary interventions identifying a category for each. Category selections are: Drug, Gene Transfer, Vaccine, Behavior, Device, and Procedure.

	Category	Intervention		Category	Intervention
	Ex. Drug	AZT		Ex. Behavior	Hypnosis
1.			6.		
2.			7.		
3.			8.		
4.			9.		
5.			10.		

OUTCOME MEASURE(S)/ENDPOINT(S): Examples – changes in cardiac output, changes in cognitive function, changes in drug or antibody.

Primary: main outcome representing a primary study question(s). (limit 250 char)_____

Secondary: outcome(s) of interest to a study, but not representing the primary study question(s). (limit 250 char)_____